
Nusrat Jahan, MD, explains the role of T-DXd as the first cytotoxic therapy in patients with HR-positive/HER2-low or -ultralow breast cancer.

Your AI-Trained Oncology Knowledge Connection!


Nusrat Jahan, MD, is an assistant professor of medicine – hematology & oncology at the O’Neal Comprehensive Cancer Center at The University of Alabama at Birmingham.